Search clinical trials for: osimertinib oral and bevazizumab intravenously

Total 15705 results

Qingdao Central Hospital

Recruiting

Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China
Qingdao Central Hospital

Recruiting

Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China
National Cancer Centre, Singapore
Taiho Pharmaceutical Co., Ltd.

Recruiting

A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

NSCLC

Singapore
Memorial Sloan Kettering Cancer Center
AstraZeneca; Genentech, Inc.

Completed

Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers

Non-small Cell Lung Cancer | EGFR-mutant Lung Cancers

United States
The Western Pennsylvania Hospital
West Penn Allegheny Health System

Withdrawn

Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy (HYDRATE)

Contrast Induced Nephropathy

United States
Li Zhang
Hubei Cancer Hospital

Not yet recruiting

SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC

Stage IV Non-small Cell Lung Cancer

China
Shanghai Cancer Hospital, China

Recruiting

Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs

Lung Cancer Stage IV

China
Wuhan Union Hospital, China

Not yet recruiting

Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT)

Non Small Cell Lung Cancer
AstraZeneca

Terminated

Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC (MINOVA)

Lung Cancer

China
Istituto Oncologico Veneto IRCCS

Active, not recruiting

First Line Osimertinib in the Real World: an Inter-regional Prospective Study (FLOWER)

EGF-R Positive Non-Small Cell Lung Cancer

Italy
Centre Hospitalier Universitaire, Amiens

Recruiting

Effect of Oral Water in Healthy Volunteers on Cardiac Output, Regional Flow and Microcirculation in Healthy Volunteers (WATERNAL)

Fluid Therapy | Pharmacodynamics | Fluid Responsiveness | Fluid Challenge | Intravenous Fluids

France
University of Southern California

Completed

Oral Hydration for Mild to Moderate Hyperglycemia in the Emergency Department

Hyperglycemia

United States
AstraZeneca

Active, not recruiting

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) (LAURA)

Non Small Cell Lung Cancer (Stage III)

United States, Spain, Taiwan, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Hungary, India, Japan, Mexico, Peru, Russian Federation, China, Malaysia, Argentina
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer | EGFR Exon20 Insertion Mutations
Shanghai East Hospital

Not yet recruiting

Circulating Tumor DNA Guided Adjuvant Chemotherapy for Biliary Tract Carcinoma

Biliary Tract Cancer

China
Pfizer

Completed

Absolute Bioavailability Of Bosutinib

Healthy

United Kingdom
Aga Khan University

Unknown

Comparison of Enteral Versus Intravenous Potassium Supplementation (EIPS)

Acute Hypokalemia

Pakistan
Western States Endurance Run Research Foundation

Unknown

The Efficacy of Oral Versus Intravenous Hypertonic Saline Administration in Runners With Exercise-Associated Hyponatremia

Exercise-associated Hyponatremia

United States
Anavex Life Sciences Corp.

Completed

Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease (ANAVEX)

Alzheimer's Disease

Australia
AstraZeneca

Completed

Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

T790M Positive NSCLC Patients

China
Sun Yat-sen University

Unknown

Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer

Non-small Cell Lung Cancer

China
Duke University

Completed

A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations

Non Small Cell Lung Cancer

United States
Ottawa Hospital Research Institute

Withdrawn

Oral Salt and Water to Prevent Contrast Nephropathy

Acute Kidney Injury

Canada
Vestre Viken Hospital Trust

Active, not recruiting

First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer (FIOL)

Lung Cancer

Denmark, Sweden, Lithuania, Norway
Molecular Partners AG

Terminated

MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC

EGFR-mutated NSCLC (Disorder)

United States
Agency for Healthcare Research and Quality (AHRQ)
Marshfield Clinic Research Foundation

Unknown

Modeling Genotype and Other Factors to Enhance the Safety of Coumadin Prescribing

Atrial Fibrillation | Pulmonary Embolism | Deep Venous Thrombosis | Heart Valve Replacement

United States
Suzhou Genhouse Bio Co., Ltd.

Recruiting

A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

Non-Small Cell Lung Cancer With EGFR Mutation

China
Blueprint Medicines Corporation

Active, not recruiting

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | EGF-R Positive Non-Small Cell Lung... and other conditions

United States, Canada, Taiwan, Korea, Republic of, Singapore, Japan, United Kingdom, France, Netherlands, Spain
AstraZeneca

Active, not recruiting

A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC (CoC)

Non-Small Cell Lung Cancer

United States, Argentina, India, Taiwan, Thailand, Vietnam
Samsung Medical Center

Withdrawn

Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)

Lung Cancer

Korea, Republic of
Medical University of Graz
Abbott Diagnostics Division

Completed

Neutrophil Gelatinase-associated Lipocalin (NGAL) and Contrast Media Induced Nephropathy

Contrast Media Induced Nephropathy (CIN)

Austria
Sun Yat-sen University

Recruiting

Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI

Neurocognitive

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-B01D1 Combined With Osimertinib Mesylate Tablets in Patients With Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Samsung Medical Center
AstraZeneca

Completed

Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC) (BLOSSOM)

Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of
AstraZeneca
Quintiles, Inc.

Completed

Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment

Solid Tumours

France, Korea, Republic of, Spain
Pfizer

Completed

A Study To Assess Absorption Of Study Drug Dacomitinib (PF-00299804), Given As An Oral Tablet Compared To An Intravenous Infusion In Healthy Volunteers

Healthy Volunteers

United Kingdom
Seoul National University Hospital
AstraZeneca; Korean Cancer Study Group

Completed

Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation

Locally Advanced or Metastatic NSCLC

Korea, Republic of
Takeda

Completed

Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults

Healthy Volunteers

United States
Jiesi Yingda Pharmaceutical Technology (Suzhou)...

Recruiting

VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer (VIC-1911)

Advanced Non-small Cell Lung Cancer

China
National and Kapodistrian University of Athens
Harvard Medical School (HMS and HSDM)

Completed

Effects of Oral vs Intravenous Glucose Administration on Novel Candidates of Energy Regulation

Overweight and Obesity

Greece
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer

Nonsmall-cell Lung Cancer

China
AstraZeneca

Completed

Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases (ODIN-BM)

Non-small Cell Lung Cancer

Sweden
Tianjin Medical University Cancer Institute and...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M (ALTN-03)

Non Small Cell Lung Cancer

China
Qingdao Central Hospital

Completed

Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer

Progression Free Survival

China
Universidad Miguel Hernandez de Elche
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la...

Not yet recruiting

Early Intervention With Therapeutic Exercise in Plantar Fasciopathy (PIPex-FP)

Plantar Fascitis

Spain
First Affiliated Hospital of Zhejiang University

Terminated

Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment

Non Small Cell Lung Cancer

China
Mark Vincent
AstraZeneca

Recruiting

Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer With Osimertinib Third-line Rechallenge (OCELOT)

Non-Small Cell Lung Cancer

Canada
LianBio LLC

Recruiting

BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations

NSCLC

China
Shanghai JMT-Bio Inc.

Active, not recruiting

JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

Local Advanced or Metastatic NSCLC | Harboring EGFR Common Mutation

China
Ain Shams University
Armed Forces Hospitals, Southern Region, Saudi Arabia

Completed

Chewing Gums to Stimulate Intestinal Motility After Cesarean Section

Postoperative Care

Saudi Arabia

Search clinical trials for: osimertinib oral and bevazizumab intravenously

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations